Focus Partners Wealth
PTGX icon

Focus Partners Wealth’s Protagonist Therapeutics PTGX Stock Holding History

Focus Partners Wealth’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-448,988
Closed -$29.8M – 2770
2025
Q3 		$29.8M Buy
+448,988
New +$25.5M 0.05% 309
2025
Q2 		– Sell
-435,097
Closed -$21M – 2115
2025
Q1 		$21M Buy
435,097
+9,540
+2% +$400K 0.05% 319
2024
Q4 		$16.4M Sell
425,557
-1,104
-0.3% -$48.1K 0.04% 356
2024
Q3 		$19.2M Buy
+426,661
New +$17.2M 0.06% 289

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Focus Partners Wealth's PTGX Position: Q4 2025 in Review

Focus Partners Wealth sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 448,988 shares — an estimated $29.8M sold.

Focus Partners Wealth first reported a position in PTGX in Q3 2024 and held it in 4 quarters. The position peaked at $29.8M in Q3 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Focus Partners Wealth reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 448,988 Protagonist Therapeutics shares in Q4 2025, an estimated $29.8M.
  • Focus Partners Wealth first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 4 quarters.
  • Focus Partners Wealth's Protagonist Therapeutics position peaked at $29.8M in Q3 2025.
  • 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Focus Partners Wealth's 13F filing for Q4 2025, filed 13 Feb 2026.